title: Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
abstract: A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and meningeal dissemination. Crizotinib was administered after the failure of first-line chemotherapy. Esophagitis and liver damage were induced by the twice-daily administration of crizotinib at 250 mg and 200 mg, respectively. The alternate-day administration of crizotinib (250 mg, twice daily) was able to control disease progression without any adverse effects for several months. We evaluated the relationship between the serum concentration of crizotinib and the development of esophagitis and liver damage. The alternate-day administration of crizotinib is one of the strategies for managing the severe toxicity of crizotinib.
authors.affiliation: Department of Respiratory Medicine, Miyagi Cancer Center, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tsukita
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Fukuhara
authors.forename: Maki
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Mami
authors.initials: M
authors.lastname: Morita
authors.forename: Aya
authors.initials: A
authors.lastname: Suzuki
authors.forename: Kana
authors.initials: K
authors.lastname: Watanabe
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Noguchi
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Kurata
authors.forename: Manabu
authors.initials: M
authors.lastname: Suno
authors.forename: Makoto
authors.initials: M
authors.lastname: Maemondo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D056486:Chemical and Drug Induced Liver Injury; D000077547:Crizotinib; D004334:Drug Administration Schedule; D004941:Esophagitis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases